Lentiviral Vectors for Gene Therapy of HIV-Induced Disease

  • R. G. Amado
  • I. S. Y. Chen
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 261)


In recent years, enormous advances have been made in our understanding of HIV pathogenesis and in the development of effective therapeutic strategies to combat HIV infection. Combination antiretroviral drugs can effectively reduce HIV RNA in peripheral blood and lymphoid tissue to undetectable levels (COLLIER et al. 1996; CAVERT et al. 1997). The advent of highly active antiretroviral therapy (HAART) initially raised expectations for the possibility of complete eradication of the virus from infected individuals. However, cell-associated virus can act as a reservoir of HIV infection in quiescent cells and remain protected from the immune system and the effects of drugs (FINZI et al. 1997; LAFEUILLADE et al. 1998). This inability to eradicate the latent viral reservoir remains perhaps the most important limitation of drug therapy as a means to cure HIV infection. Other important limitations of antiretroviral drugs include the uniform eventual development of drug resistance, severe toxicity, and cumbersome schedules that hinder compliance.


Long Terminal Repeat CD34 Positive Cell Ciency Virus Human Immunode Reporter Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284–291PubMedGoogle Scholar
  2. Akkina RK, Rosenblatt JD, Campbell AG, Chen IS, Zack JA (1994) Modeling human lymphoid precursor cell gene therapy in the SCID-hu mouse. Blood 84:1393–1398PubMedGoogle Scholar
  3. Amado RG, Jamieson BD, Cortado R, Cole SW, Zack JA (1999a) Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. J Virol 73:6361–6369PubMedGoogle Scholar
  4. Amado RG, Mitsuyasu RT, Symonds G, Rosenblatt JD, Zack J, Sun LQ, Miller M, Ely J, Gerlach W (1999b) A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 10:2255–2270PubMedCrossRefGoogle Scholar
  5. Amado RG, Rosenblatt JD, Zack JA, et al. (1999c) A phase I trial of autologous CD34+ cells transduced with an anti-HIV ribozyme. Abstract. 6th Conference on Retroviruses and Opportunistic InfectionsGoogle Scholar
  6. An DS, Koyanagi Y, Zhao JQ, Akkina R, Bristol G, Yamamoto N, Zack JA, Chen IS (1997) High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. J Virol 71:1397–1404PubMedGoogle Scholar
  7. An DS, Morizono K, Li QX, Mao SH, Lu S, Chen IS (1999) An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol 73:7671–7677PubMedGoogle Scholar
  8. An DS, Wersto RP, Agricola B, Metzger M, Lu S, Amado RG, Chen ISY, Donahue RE (2000) Marking and gene expression by a lentiviral vector in transplanted human and non-human primate CD34 + Cells. J Virol 74:1286–1295PubMedCrossRefGoogle Scholar
  9. Bodine DM, Moritz T, Donahue RE, Luskey BD, Kessler SW, Martin DI, Orkin SH, Nienhuis AW, Williams DA (1993) Long-term in vivo expression of a murine adenosine deaminase gene in rhesus monkey hematopoietic cells of multiple lineages after retroviral mediated gene transfer into CD34 + bone marrow cells. Blood 82:1975–1980PubMedGoogle Scholar
  10. Bonyhadi ML, Moss K, Voytovich A, Auten J, Kalfoglou C, Plavec I, Forestell S, Su L, Bohnlein E, Kaneshima H (1997) RevM 10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication. J Virol 71:4707–4716PubMedGoogle Scholar
  11. Bukovsky AA, Song JP, Naldini L (1999) Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73:7087–7092PubMedGoogle Scholar
  12. Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L, Kohn DB, Crooks GM (1999) Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 96:2988–2993PubMedCrossRefGoogle Scholar
  13. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288:669–672PubMedCrossRefGoogle Scholar
  14. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA, Haase AT (1997) Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276:960–964PubMedCrossRefGoogle Scholar
  15. Challita PM, Kohn DB (1994) Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 91:2567–2571PubMedCrossRefGoogle Scholar
  16. Chinnasamy D, Chinnasamy N, Enriquez MJ, Otsu M, Morgan RA, Candotti F (2000) Lentiviralmediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 96: 1309–1316PubMedGoogle Scholar
  17. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, Corey L (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 334:1011–1017PubMedCrossRefGoogle Scholar
  18. Corbeau P, Wong-Staal F (1998) Anti-HIV effects of HIV vectors. Virology 243:268–274PubMedCrossRefGoogle Scholar
  19. Donahue RE, Bunnell BA, Zink MC, Metzger ME, Westro RP, Kirby MR, Unangst T, Clements JE, Morgan RA (1998) Reduction in SIV replication in rhesus macaques infused with autologous lymphocytes engineered with antiviral genes. Nat Med 4:181–186PubMedCrossRefGoogle Scholar
  20. Douglas J, Kelly P, Evans JT, Garcia JV (1999) Efficient transduction of human lymphocytes and CD 34+ cells via human immunodeficiency virus-based gene transfer vectors. Hum Gene Ther 10:935–945PubMedCrossRefGoogle Scholar
  21. Duan L, Bagasra O, Laughlin MA, Oakes JW, Pomerantz RJ (1994) Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc Natl Acad Sci USA 91:5075–5079PubMedCrossRefGoogle Scholar
  22. Evans JT, Garcia JV (2000) Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum Gene Ther 11:2331–2339PubMedCrossRefGoogle Scholar
  23. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295–1300PubMedCrossRefGoogle Scholar
  24. Geretti AM (1999) Simian immunodeficiency virus as a model of human HIV disease. Rev Med Virol 9:57–67PubMedCrossRefGoogle Scholar
  25. Gothot A, van der Loo JC, Clapp DW, Srour EF (1998) Cell cycle-related changes in repopulating capacity of human mobilized peripheral blood CD34(+) cells in non-obese diabetic/severe combined immune-deficient mice. Blood 92:2641–2649PubMedGoogle Scholar
  26. Jamieson BD, Zack JA (1998) In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 72:6520–6526PubMedGoogle Scholar
  27. Jones RJ, Wagner JE, Celano P, Zicha MS, Sharkis SJ (1990) Separation of pluripotent haematopoietic stem cells from spleen colon-forming cells. Nature 347:188–189PubMedCrossRefGoogle Scholar
  28. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM (1997) Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genetics 17:314–317CrossRefGoogle Scholar
  29. Kaptein LC, Van Beusechem VW, Riviere I, Mulligan RC, Valerio D (1997) Long-term in vivo expression of the MFG-ADA retroviral vector in rhesus monkeys transplanted with transduced bone marrow cells. Hum Gene Ther 8:1605–1610PubMedCrossRefGoogle Scholar
  30. Klug CA, Cheshier S, Weissman IL (2000) Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny. Blood 96:894–901PubMedGoogle Scholar
  31. Kohn DB, Bauer G, Rice CR, Rothschild JC, Carbonaro DA, Valdez P, Hao Q, Zhou C, Bahner I, Kearns K, Brody K, Fox S, Haden E, Wilson K, Salata C, Dolan C, Wetter C, Aguilar-Cordova E, Church J (1999) A clinical trial of retro viral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 94:368–371PubMedGoogle Scholar
  32. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA, Crooks G, Kapoor N, Elder M, Wara D, Bowen T, Madsen E, Snyder FF, Bastian J, Muul L, Blaese RM, Weinberg K, Parkman R (1998) T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD 34+ cells in ADA-deficient SCID neonates. Nat Med 4:775–780PubMedCrossRefGoogle Scholar
  33. Koka PS, Jamieson BD, Brooks DG, Zack JA (1999) Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 73:9089–9097PubMedGoogle Scholar
  34. Korin YD, Zack JA (1998) Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 72:3161–3168PubMedGoogle Scholar
  35. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C (1998) Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of < 200 copies/mL. J Infect Dis 177:235–238PubMedCrossRefGoogle Scholar
  36. Lewis P, Hensel M, Emerman M (1992) Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 11:3053–3058PubMedGoogle Scholar
  37. Lisziewicz J, Sun D, Smythe J, Lusso P, Lori F, Louie A, Markham P, Rossi J, Reitz M, Gallo RC (1993) Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc Nat′1 Acad Sci-USA 90:8000–8004CrossRefGoogle Scholar
  38. Lu Y, Planelles V, Li X, Palaniappan C, Day B, Challita-Eid P, Amado R, Stephens D, Kohn DB, Bakker A, Fay P, Bambara RA, Rosenblatt JD (1997) Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem 272:14523–14531PubMedCrossRefGoogle Scholar
  39. Miller DG, Adam MA, Miller AD (1990) Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239–4242PubMedGoogle Scholar
  40. Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci-USA 94: 10319–10323PubMedCrossRefGoogle Scholar
  41. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72:8150–8157PubMedGoogle Scholar
  42. Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE (1999) Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283:682–686PubMedCrossRefGoogle Scholar
  43. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D (1996a) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263–267PubMedCrossRefGoogle Scholar
  44. Naldini L, Blomer U, Gage FH, Trono D, Verma IM (1996b) Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Nat’l Acad Sci-USA 93:11382–11383CrossRefGoogle Scholar
  45. Peters SO, Kittler EL, Ramshaw HS, Quesenberry PJ (1996) Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood 87:30–37PubMedGoogle Scholar
  46. Planelles V, Bachelerie F, Jowett JB, Haislip A, Xie Y, Banooni P, Masuda T, Chen IS (1995) Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol 69:5883–5889PubMedGoogle Scholar
  47. Plavec I, Agarwal M, Ho KE, Pineda M, Auten J, Baker J, Matsuzaki H, Escaich S, Bonyhadi M, Bohnlein E (1997) High transdominant RevMIO protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS. Gene Ther 4:128–139PubMedCrossRefGoogle Scholar
  48. Poeschla EM, Wong-Staal F, Looney DJ (1998) Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 4:354–357PubMedCrossRefGoogle Scholar
  49. Ranga U, Woffendin C, Verma S, Xu L, June CH, Bishop DK, Nabel GJ (1998) Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci USA 95:1201–1206PubMedCrossRefGoogle Scholar
  50. Shen H, Cheng T, Preffer FI, Dombkowski D, Tomasson MH, Golan DE, Yang O, Hofmann W, Sodroski JG, Luster AD, Scadden DT (1999) Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol 73:728–737PubMedGoogle Scholar
  51. Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, Chameau P (2000) The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96:4103–4110PubMedGoogle Scholar
  52. Spina CA, Guatelli JC, Richman DD (1995) Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 69:2977–2988PubMedGoogle Scholar
  53. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E (1991) Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. JVirol 65:6811–6816Google Scholar
  54. Sun LQ, Pyati J, Smythe J, Wang L, Macpherson J, Gerlach W, Symonds G (1995) Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci USA 92:7272–7276PubMedCrossRefGoogle Scholar
  55. Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE, Dunbar CE (1998) Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 92:1131–1141PubMedGoogle Scholar
  56. Uchida N, Sutton RE, Friera AM, He D, Reitsma MJ, Chang WC, Veres G, Scollay R, Weissman IL (1998) HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA 95:11939–11944PubMedCrossRefGoogle Scholar
  57. van den Driessche T, Chuah MK, Chiang L, Chang HK, Ensoli B, Morgan RA (1995) Inhibition of clinical human immunodeficiency virus (HIV) type 1 isolates in primary CD4+ T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 69:4045–4052Google Scholar
  58. von Schwedler U, Kornbluth RS, Trono D (1994) The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 91:6992–6996CrossRefGoogle Scholar
  59. Weinberg JB, Matthews TJ, Cullen BR, Malim MH (1991) Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 174:1477–1482PubMedCrossRefGoogle Scholar
  60. Xu LC, Karlsson S, Byrne ER, Kluepfel-Stahl S, Kessler SW, Agricola BA, Sellers S, Kirby M, Dunbar CE, Brady RO (1995) Long-term in vivo expression of the human glucocerebrosidase gene in non-human primates after CD 34+ hematopoietic cell transduction with cell-free retroviral vector preparations. Proc Natl Acad Sci USA 92:4372–4376PubMedCrossRefGoogle Scholar
  61. Yang AG, Bai X, Huang XF, Yao C, Chen S (1997) Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci-USA 94:11567–11572PubMedCrossRefGoogle Scholar
  62. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Chameau P (2000) HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173–185PubMedCrossRefGoogle Scholar
  63. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72:9873–9880PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • R. G. Amado
    • 1
  • I. S. Y. Chen
    • 2
  1. 1.Department of Medicine, Division of Hematology/OncologyUCLA School of MedicineLos AngelesUSA
  2. 2.Department of Microbiology and Immunology and Medicine, and UCLA AIDS InstituteUCLA School of MedicineLos AngelesUSA

Personalised recommendations